脾多肽注射液联合化疗治疗广泛期小细胞肺癌临床分析

Clinical observation of lienal polypeptide injection combined with chemotherapy in treating extensive small cell lung cancer

目的探讨广泛期小细胞肺癌(SCLC)患者在化疗中应用脾多肽注射液对血小板计数、免疫指标及近期临床疗效的影响。方法将2013年1月1日至2016年6月1日该院收治的80例广泛期SCLC患者随机分为治疗组(化疗同步联合脾多肽注射液治疗)和对照组(单纯化疗),每组40例。监测患者的血小板及外周血T细胞亚群变化,同时观察近期临床疗效。结果治疗组化疗中血小板降低至3~4度的患者占比明显低于对照组,化疗后T细胞亚群分析各项免疫学指标显著优于对照组,差异均有统计学意义(P<0.05或<0.01);治疗组客观有效率(85.0%)优于对照组(72.5%),但差异无统计学意义(P>0.05)。结论在广泛期SCLC患者化疗过程中同步使用脾多肽注射液能降低化疗相关血液毒性,改善患者免疫功能,能在一定程度上提高治疗有效率。

Objective To investigate the influence of lienal polypeptide injection on platelet count,immunity index and short-term clinical efficacy of patients with extensive small cell lung cancer（SCLC） during chemotherapy. Methods Eighty patients with extensive SCLS in the hospital from January 1st 2013 to June 1st 2016 were selected and randomly divided into the treatment group,patients in which received chemotherapy combined with lienal polypeptide injection,and the control group,patients in which received chemotherapy only,40 cases in each group. The short-term clinical effects,platelet count and T cell subclasses in peripheral blood of patients were recorded and observed. Results The proportion of patients with blood platelet reduced to 3-4° during chemotherapy in the treatment group was lower than that in the control group,while immunity indexes of T cell subclasses after chemotherapy in the treatment group were obviously superior to that in the control group,and the differences both had statistical significance（P〈0.05 or 0.01）. The objective response rate in the treatment group（85.0%） was better than that in the control group（72.5%）,but the difference was not statistically significant（P〉0.05）. Conclusion During the chemotherapy of patients with extensive SCLC,application of lienal polypeptide injection simultaneously can reduce the hematotoxicity related to chemotherapy,improve patients＇ immunologic function and increase effective rate to some extent.